Please select the option that best describes you:
What treatment strategies would you utilize in a patient with newly diagnosed HLA-B27+ axial spondyloarthritis (with active and chronic sacroiliitis on MRI) and recent diagnosis of MS that is well-controlled MS ocrelizumab given the need to avoid TNF inhibitors?
Patient did not have improvement with NSAIDs. Would you consider IL-17? Do you consider reduced dosing schedules in the setting of dual biologic use?